The concept of myocardial ischemic 'preconditioning' protection; (ii) summarize, for each of these multiple (PC) has been with us since 1986 [1] . A tremendous body scenarios, the potential benefits that might be achieved in of research over the last 15 years has documented this the implementation of PC as a therapeutic strategy; (iii) phenomenon in virtually every species tested, with both an outline, for each of the relevant clinical settings, a proearly and late phase of PC-induced cardioprotection, posed design for the multicenter trials that will be needed manifest |5-30 min and 12-24 h after the PC trigger, to prospectively test the clinical utility of PC-based having been identified. A host of additional studies have interventions; and (iv) discuss the caveats and problems yielded insight into the cellular mediators and complex that may be encountered in the clinical application of second messenger pathways that purportedly contribute to ischemic preconditioning. the protection achieved with brief antecedent PC ischemia, with the currently favored paradigm involving initial stimulation of one or more G protein-coupled receptors;
1 . The 'screening' models subsequent activation of multiple 'in parallel' or 'in series' kinases (i.e. including, among others, the´-isoform of 1 .1. Isolated human myocardial samples protein kinase C and one or more isoforms of p38 mitogen activated protein kinase); followed by phosphorylation and Among the numerous studies that suggest ischemic activation of a membrane-bound end-effector, possibly the preconditioning can occur in the human heart, perhaps the sarcolemmal and / or mitochondrial K channel. These most compelling and direct evidence has been obtained ATP mechanistic studies have, as an ancillary benefit, provided using isolated human atrial and ventricular tissue. For a rational framework for the identification of pharmacologexample, human cardiomyocytes exposed to a sustained ic agents that, when given in lieu of brief ischemia, may episode of simulated ischemia showed enhanced survival effectively mimic the benefits of conventional ischemic when pretreated with an antecedent brief ischemic stimulus PC.
[2], isolated cardiac trabeculae exhibited enhanced rePerhaps most importantly, a substantial amount of covery of function following reoxygenation when preevidence favors the concept that ischemic preconditioning treated with brief bouts of pacing and hypoxia [3] , and (both early and delayed) can occur in human hearts.
right atrial samples suffered less irreversible ischemiaHowever, the translation of ischemic preconditioning from induced injury (assessed by creatine kinase (CK) release the experimental laboratory to clinical utility has been and tetrazolium staining) when preconditioned with predisappointing and slow. Our goals in this manuscript are ceding bouts of brief ischemia [4] . to: (i) review the clinical models and scenarios in which Preconditioning of isolated human myocardial tissue conventional ischemic PC and / or pharmacologic PCclearly offers no direct benefit with regard to patient care. mimetic agents have shown promise in eliciting cardioNonetheless, this model has provided valuable insight into the contribution-and possible clinical relevance-of adenosine, protein kinase C (PKC), the ATP-sensitive prior to the angioplasty procedure preconditioned the heart trials. However, as reduction of infarct size is the undisand significantly reduced the likelihood of post-procedural puted hallmark of PC-induced cardioprotection [7] , it must CK release [13] . be emphasized that the most meaningful application of this It must be acknowledged that the increased tolerance to model in the screening of PC mimetics must include a ischemia seen with repeated balloon inflations may, in direct or surrogate assessment of myocyte necrosis (Table  some compared with controls that received saline. Conversely, in manifestations of ischemia were attenuated during the patients given the adenosine receptor antagonists aminosecond phase of pacing compared to the first [25] . As with phylline [17] or bamiphylline [18] before angioplasty, repeated balloon inflations during angioplasty, vasodilation there was no significant change in ST segment shift on and recruitment of collaterals may, in part, contribute to consecutive balloon inflations. Other studies in patients this enhanced tolerance to repeated demand ischemia. undergoing coronary angioplasty have identified myocarHowever, this observation, termed the 'warm-up' phenomdial opioid and bradykinin receptors as functionally imenon, has been suggested to be a clinical analogue of portant in preconditioning, i.e. a placebo-controlled study ischemic preconditioning [23, 24] . of naloxone, an opioid receptor antagonist, given 15 min With regard to clinical utility, there is no doubt that a before angioplasty resulted in abolition of the precondiwarm-up phase prior to heavy exertion is prudent in the tioning response as assessed by ST segment shift and chest coronary artery disease patient; this may precondition the pain severity [19] . In addition, involvement of the K heart and allow better exercise performance without is-ATP channel was shown in a report by Tomai et al. [20] , where chemia. The scenario of exercise-induced demand isglibenclamide, a selective K channel blocker adminischemia may further represent a relatively simple and ATP tered prior to angioplasty abrogated the beneficial effect of focused platform for clinical trials seeking to evaluate the sequential balloon inflations. Finally, Leesar and colefficacy of PC mimetic candidates (Table 1 ). While leagues [21] recently demonstrated that the NO donor enthusiasm for this concept must be tempered by recent nitroglycerin could mimic the delayed preconditioning studies implicating possible mechanistic differences bephenomenon in the setting of angioplasty. Specifically, tween conventional ischemic PC and the warm-up phepatients receiving nitroglycerin showed less initial ST nomenon-most notably with regard to adenosine and the segment elevation and lack of a change in ST elevation on K channel [26] [27] [28] [29] -continued investigation of adeno-ATP subsequent compared to a first balloon inflation, while no sine receptor agonists, K channel openers, opioids and ATP benefit was seen in placebo-treated controls. Taken toother candidate mimetics in this model is nonetheless gether, these studies support the presence of both an early warranted. To address the early phase of protection, and late phase of PC-and PC mimetic-induced protection patients would be randomized to receive the test agent or in patients undergoing angioplasty.
placebo at 30 min prior to a standard exercise test. As in Would implementation of PC-based therapeutic stratethe conventional 'warm-up' protocols, typical endpoints gies offer significant clinical benefit to the angioplasty would include: exercise duration; heart rate and blood patient? Reduction of chest pain, ventricular ectopic activipressure at peak exercise; the time required to achieve 1 ty, etc. would clearly be of merit. However, from a mV of ST segment depression; and maximum ST segment practical standpoint, the current widespread use and docudepression. Although assessment of cardiac enzyme remented efficacy of other protective modalities such as lease (i.e. markers of necrosis) would probably not yield stents and glycoprotein IIb / IIIa inhibitors may, even in fruitful results in this model, a more comprehensive and difficult angioplasty procedures, leave little scope for an invasive study design might further measure the developadditive improvement in clinical outcome with the adment of thallium perfusion defects or regional wall motion juvant application of PC mimetics or conventional isabnormalities by echocardiography. A similar strategy chemic PC. Rather, as with the in vitro models, angioplascould, in theory, be employed to evaluate the efficacy of ty is perhaps best suited to the initial screening of PC agents targeted at evoking a delayed protective response by mimetic candidates aimed at either the early or delayed administering placebo or the PC mimetic drug 24 h before phase of cardioprotection, particularly if enzymatic indices exercise. However, as the existence of a delayed exerciseof irreversible myocyte injury are incorporated into the induced 'warm-up' effect is in dispute [24] , the relevance study design (Table 1) .
of this approach may be questionable.
.2. Coronary artery bypass surgery . The 'prophylaxis' models
As PC-based strategies are, by definition, applied before 2 .1. Repeated exercise and the 'warm-up' phenomenon an ischemic event, coronary artery bypass surgery is among the few clinical scenarios in which preischemic It is well-documented that patients who have two intervention is both logical and feasible (Table 1) . Howsequential and identical exercise tests with a |10-30 min ever, studies to date with preconditioning in patients period of rest in between tend to perform better-i.e. have undergoing coronary bypass surgery have yielded apparless chest pain, less ST segment elevation, and longer ently discordant results. Yellon et al. [30] , using myocarexercise duration-on the second test vs. the first [22] [23] [24] . dial high energy phosphate content during sustained norAnalogous findings have been observed in the catheterizamothermic cross-clamp fibrillation as their primary endtion laboratory when two episodes of pacing-induced point, showed better preservation of ATP levels in patients ischemia were separated by a brief rest (no pacing) period: preconditioned with two antecedent 3-min periods of aortic cross clamping (the brief ischemic stimulus) vs. nonadenosine agonists, delta opioids, bradykinin, and other preconditioned controls. In a follow-up study by the same compounds targeting the K channel would also be ATP group [31] , troponin release during cardiac surgery was logical choices. Similarly, to test the delayed phase of reportedly attenuated with PC although, interestingly, no protection, a PC-mimetic candidate (such as, for example, difference in ATP levels was seen. Beneficial effects of nitroglycerin) could be administered 24 h prior to surgery. preconditioning have also been described using more
As discussed previously, definitive conclusions concerning conventional surgical methods and endpoints. For example, the efficacy of these PC-based interventions will require an Illes and Swoyer [32] assigned patients to receive 1 min of assessment of peri-operative Q wave myocardial infarcaortic cross clamping during normothermic cardiopulmontion, as well as the post-operative release of CK-MB and ary bypass (CPB) or a matched control period (CBP alone) troponin I. Ancillary clinical endpoints would include periprior to performing coronary grafts under cold cardioplegic operative mortality, the incidence of congestive heart arrest. While there were no differences in post-operative failure, a detailed assessment of the requirement for postmorbidity and mortality between groups, significant imoperative inotropic support (duration, dose and total numprovements in functional recovery (i.e. improved cardiac ber of treatments), as well as a comprehensive analysis of index; lower use of inotropic support) were seen in the post-operative arrhythmias (type and duration of arrhythpreconditioned cohort.
mias and administration of antiarrhythmic drugs). AlIn contrast to these favorable reports, others have found though assessment of functional recovery will not, in itself, no benefit-and, indeed, worse outcomes-with PC. Speyield conclusive results, a measure of post-operative cifically, Perrault and colleagues [33] observed that CK function (i.e. ejection fraction from radionuclide venrelease was exacerbated and lactate production was entriculograms or 2-D echocardiograms) should nonetheless hanced in patients first preconditioned with 3 min of aortic be obtained. cross-clamping before instituting warm retrograde cardiopDespite the relative ease with which the requisite legic arrest. Similarly, preconditioning with a 5 min period pretreatment can be administered in patients undergoing of global ischemia was associated with an increased bypass surgery, three fundamental issues will complicate depletion of ATP and a non-significant trend toward the assessment of the efficacy of preconditioning in this augmented CK and troponin release following the crossmodel. First, the pre-operative administration of opioids clamp period, with no differences in hemodynamic remay precondition the heart [39] . Similarly, insight from covery or post-operative complications between the control experimental animal models has revealed that anesthetic and PC groups [34] . agents (i.e. halothane and others) and CPB per se are Comparison of these studies and resolution of the cardioprotective [40] . It is therefore possible that these two seemingly disparate findings is confounded by differences factors may attenuate or overwhelm any benefit of the test in surgical technique (i.e. normothermic cross-clamp fibrilagent, particularly if all three stimuli elicit their protective lation, normothermic cardioplegic arrest, hypothermic careffects via the same cellular pathways. Finally, modern dioplegia) as well as the diversity of endpoints used surgical techniques-in particular, cardioplegia-are, in (metabolic parameters, CK / troponin release, hemodynamic themselves, highly effective in limiting ischemic damage; indices, need for inotropes, etc.). This latter issue may be as a result, with the exception of high risk coronary bypass especially important. While there is no question that surgery or instances in which the distribution of cardioppreconditioning renders the heart resistant to infarction, it legia is heterogeneous, the incidence of peri-operative is equally well-recognized that preconditioning does not infarction is low [33, 36] . Thus, it will be a challenge to exert an independent beneficial effect on recovery of achieve a statistically significant, additive benefit of an function of the viable but stunned myocardium [7] . As ancillary PC-based therapy in the setting of coronary artery post-bypass pump dysfunction is primarily a consequence bypass surgery. of stunning [35] , studies relying exclusively on surrogate indices such as of functional recovery must be interpreted 2 .3. Transplant with caution.
Given these important caveats, what would constitute a A third logical and feasible scenario in which PC-based rationally designed protocol to evaluate the efficacy of PC interventions may provide benefit is the augmented prein patients undergoing coronary artery bypass surgery? servation of hearts harvested for transplantation (Table 1) . This model is especially well-suited to the controlled Although the efficacy of preconditioning in this setting is administration of either brief ischemia per se (i.e. intermitnot well-explored, there is experimental evidence that PC tent aortic cross-clamping) or a benign PC-mimetic agent and the use of PC-mimetics is beneficial. For example, prior to the onset of CPB. To test the early phase of Landymore et al. [41] recently showed that PC attenuated protection, the PC stimulus would obviously be given myocardial stunning and preserved high-energy phosphates immediately (|10-30 min) before the event. In this regard, after cardiac transplantation in sheep, while pharmacologic recent studies have employed adenosine and nicorandil (a PC with phenylephrine improved functional recovery in K channel opener) as the test agent [36] [37] [38] ; however, transplanted rabbit hearts [42] . Favorable results have also ATP been reported in rat transplant models: ischemic PC was described with preinfarct angina may, in some patients, be associated with improved functional recovery and reduced due in part to collateral recruitment. CK release, with further synergistic benefit achieved by Pharmacologic treatment of acute MI arguably repre-
combined administration of the Na -H exchange inhibsents the most attractive and lucrative conceptual target for itor cariporide together with brief antecedent ischemia PC-based therapies. Practical application of PC mimetics [43] . Similarly, a brief pre-storage period of heat-enhanced in this setting is, however, undermined by the fact that, in ischemic PC translated into improved functional recovery contrast to coronary artery bypass surgery and the other in the transplanted rat heart [44] .
'prophylaxis' models, acute MI is not a predictable or Taken together these studies support a role for PC, or 'planned' ischemic event. As a result, the requisite preefforts to mimic its metabolic pathways, as a means of ischemic administration of the mimetic agent will be conferring clinical benefit. In view of the shortage of difficult to achieve (Table 1) . suitable donors relative to recipients there has been an One compromise to this challenge might be to selectiveinterest to expand donor populations to include not only ly focus on a clinical sub-population with a high probabilithe brain-dead patient-in which, interestingly, antecedent ty of developing acute MI-i.e. patients with unstable PC ischemia may be rendered ineffective in eliciting angina-in an effort to determine whether treatment with protection [45] -but to those where cardiopulmonary PC-based therapies would avert infarction. At the onset of 'death' has ensued (i.e. non-heart-beating donors). It is in unstable angina, patients would be randomized to receive this setting that PC-mimetics, as well as other modalities either placebo or the test agent. The primary endpoint aimed at tissue preservation, may have their greatest would clearly be the development of Q wave or non-Q impact. PC-mimetics would optimally be given to the wave infarction, as determined by the measurement of CK heart-vital donor at |30 min prior to harvesting the organ, and troponin I release, recognizing that these indices are or, alternatively, to the heart itself immediately after relatively crude measures of infarct size. Surrogate indices explantation. Meaningful clinical endpoints in the evaluaof protection employed in previous angina-acute MI tion of PC in this setting would include transplant organ studies-i.e. incidence of congestive heart failure and function (radionuclide ventriculogram, echocardiogram), shock, recovery of LV function, in-hospital and long-term surrogate enzymatic indices of myocyte necrosis, incidence mortality-would also be assessed. In addition, as some of of heart failure, patient survival, etc.
the patients would undoubtedly go on to require angioplasty and / or stenting, coronary artery bypass grafting, etc. plans to prospectively compare the incidence and type of revascularization procedures in placebo versus PC 3 . The 'holy grail': PC-based strategies for the mimetic-treated groups should also be incorporated into treatment of acute myocardial infarction the study design.
It is important to recognize that, in addition to the If brief antecedent ischemia 'preconditions' the human challenges posed by the execution of such a study, heart, this benefit should, in concept, be manifest in the interpretation of the results may also prove to be difficult. patient with angina prior to acute myocardial infarction
The assumption inherent in this approach is that the (MI). In addition, the time course of this effect should mimetic agent would be capable of augmenting any reflect the established temporal characteristics of ischemic protective effect evoked by the angina per se, an issue PC. Although disparate results have been obtained [46] which, as discussed previously, may be problematic if both considerable evidence suggests that preinfarct angina is, protective stimuli share a common cellular mechanism. A indeed, associated with smaller CK-determined infarct second potentially confounding issue may be the antisizes [47] [48] [49] , with protection only achieved in those anginal drugs these patients would undoubtedly be receivpatients experiencing angina within 24 h of the onset of ing: it could be argued that pharmacologic resolution of the infarction [50] . Reported ancillary benefits of preinfarct angina might abrogate its protective effect while, converseangina include significant reductions in mortality, attenualy, several anti-anginal drugs (i.e. nitroglycerin; nicorandil) tions in the incidence of heart failure, cardiogenic shock are PC-mimetic candidates. Rational evaluation of PC and serious tachyarrhythmias, as well as improved remimetic strategies in the setting of acute MI may therefore covery of LV contractile performance [47, 49, 51, 52] . Interstill be a distant-albeit highly laudable-goal. estingly, the favorable effects of preinfarct angina may extend beyond the cardiomyocyte, i.e. the smaller infarct sizes in the angina cohorts may also be due in part to an 4 . The underlying problem: preconditioning the aged enhanced efficacy of thrombolysis, achieved via release of and diseased heart adenosine-a potent inhibitor of platelet aggregationduring the brief antecedent ischemic episodes [53, 54] .
Among the host of experimental studies conducted to However, as in instances of angioplasty and repeated date on the topic of preconditioning, it is perhaps remarkexercise, it must be cautioned that the improved outcome able that the vast majority have employed healthy, juvenile or adult animals. Only a handful of investigations have in clinical trials of heart transplant and coronary artery explored PC-induced cardioprotection in senescence or in bypass surgery. In contrast, the requirement for pretreatthe presence of underlying cardiovascular disease-the ment will make therapeutic application of PC-mimetics in specific populations in which clinical application of PC the unpredictable setting of acute MI considerably more would be most relevant.
challenging. It is important that all clinical studies of PC Studies of PC in aged and diseased models have yielded and PC-based therapies endeavor to include, as a primary discrepant results. There is evidence that, in the senescent endpoint, a direct or surrogate assessment of myocyte rat heart, antecedent PC ischemia does not improve the necrosis, the undisputed hallmark of PC-induced cardioprecovery of post-ischemic ventricular function and, of rotection. Moreover, any large-scale clinical application of greater concern, fails to elicit reductions in infarct size PC-based strategies will clearly require definitive evidence [55] [56] [57] [58] . Of note, however, all of these previous studies for the continued efficacy of ischemic preconditioning in were conducted in isolated buffer-perfused hearts. In the aged and diseased heart. marked contrast, in the in vivo rabbit model of acute MI, infarct size reduction with PC was manifest-with no loss in efficacy-in middle-aged and old cohorts exhibiting R eferences definitive hallmarks of cardiovascular aging [59] . A similar lack of consensus is seen in the clinical literature: of the [ ease models, it is perhaps encouraging that reduction of streptozotocin-induced diabetes [64] [65] [66] . Disturbingly, Adenosine preconditioning of human myocardium is dependent diabetes, etc.) into the study protocol.
[10] Cribier A, Korsatz L, Koning R et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am
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While tremendous effort has gone into the determination of 
